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Background: Cardiovascular disease (CVD) is the leading cause of death in women, responsible for approximately a
third of all female deaths. Pregnancy complications are known to be associated with a greater risk of incident CVD
in mothers. However, the relationships between pregnancy loss due to miscarriage, stillbirth, or therapeutic
abortion, and future maternal cardiovascular health are under-researched. This study seeks to provide an up-to-date
systematic review and meta-analysis of the relationship between these three forms of pregnancy loss and the
subsequent development of CVD.
Methods: This systematic review will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis
checklist (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) Checklist. A systematic
search will be undertaken using publications identified in MEDLINE (PubMed), Scopus, Web of Knowledge, the CINA
HL Nursing Database, and the Cochrane Library. The eligibility of each publication will be determined by predefined
selection criteria. The quality of the included studies will be rated using the Newcastle-Ottawa Scale. Pooled
measures of association will be computed using random-effects model meta-analyses. Between-study
heterogeneity will be assessed using the I2 statistic and the Cochrane χ2 statistic. Small study effects will be
evaluated for meta-analyses with sufficient studies through the use of funnel plots and Egger’s test.
Discussion: The results of this systematic review will discuss the long-term risks of multiple types of cardiovascular
disease in women who have experienced miscarriage, stillbirth, and/or therapeutic abortion. It will contribute to the
growing field of cardio-obstetrics as the first to consider the full breadth of literature regarding the association
between all forms of pregnancy loss and future maternal cardiovascular disease.
Systematic review registration: PROSPERO registration number [CRD42020167587]
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Cardiovascular disease (CVD) encompasses a number of
different conditions affecting the cardiovascular system,
such as stroke and myocardial infarction (MI) [1, 2]. CVD
presents one of the largest global public health challenges,
causing more deaths globally than any other cause; ap-
proximately 32% of global deaths and a third of all female
deaths in 2017 [1, 3–5]. It is also the leading cause of non-
communicable disability-adjusted life years lost [6]. The
majority of the global health burden, of both death and
disability, associated with CVDs can be attributed to two
main subtypes: coronary heart disease (CHD), also known
as ischemic heart disease, and stroke [7–9].
Given that most CVD-related deaths and disabilities are
due to modifiable or preventable risk factors, it remains a
top priority for public health and preventative measures
globally. However, CVD research has historically been fo-
cused on men—with recent textbooks still describing the
common male CVD presentation as the standard presen-
tation [10]. This is beginning to change. The recent identi-
fication of female-specific factors associated with a greater
CVD risk provides the potential to implement effective
and targeted preventative measures to decrease disease
burden at an individual and population level [11].
Female-specific risk factors known to be associated
with greater CVD risk include early menopause, early
menarche, and hysterectomy [12]. Changes that occur
during pregnancy, such as pre-eclampsia, gestational dia-
betes, and preterm birth, have also been linked to
greater CVD risk in women [11].
Pregnancy loss through miscarriage is, sadly, a common
pregnancy complication. Up to 60% of all pregnancies end
in miscarriage [13, 14], while 2% of British women annu-
ally have a therapeutic abortion (henceforth referred to as
abortion) [15] and 1.8% of babies are stillborn worldwide
(0.3% in developed countries) [16]. Prior studies have indi-
cated a greater CVD risk for women who have repeated
miscarriages or a stillbirth [11, 12, 17]. However, previous
systematic reviews on this topic do not incorporate the
most up-to-date publications, have disparate inclusion
and exclusion criteria, and between-study heterogeneity
[11, 12]. As a result, there is a lack of clarity about (1) the
absolute and relative magnitude of CVD risk after miscar-
riage and stillbirth, (2) the risk associated with recurrent
pregnancy loss, and (3) the risk of different subtypes of
CVD, as prior reviews at most evaluated CVD, CHD, and
stroke. Furthermore, no reviews evaluated CVD risk after
abortions, although this provides a natural control for the
miscarriage analyses, as both result in cessation of a preg-
nancy, primarily in the first 12 weeks of gestation.
To address these knowledge gaps, a review summariz-
ing this area of research is needed, and a systematic re-
view protocol was developed to assist the identification,
evaluation, and interpretation of all relevant research.All authors followed this protocol during the literature
review and meta-analysis of published studies. Existing
guidelines for meta-analyses, systematic reviews, and
protocols were consulted (MOOSE, Cochrane Hand-
book, Guidance on the Conduct of Narrative Synthesis
in Systematic Reviews, PRISMA, and PRISMA-P) in the
development of this protocol [18–22].
This study seeks to provide an up-to-date summary of
the evidence for the long-term CVD risk for women who
have experienced pregnancy loss compared to women who
have not. It serves as an update to, and expansion of, a
similar systematic review and meta-analysis carried out in
2011 [17], which focused on the association between mis-
carriage and future maternal CVD specifically. This review
has wider inclusion criteria, through the addition of still-
birth and therapeutic abortion as exposures and added sen-
sitivity analyses to increase methodological robustness. All
methodological changes have been designed a priori and
are clearly outlined in this protocol. PRISMA and MOOSE
checklists will be completed for this review [18, 21].Methods/design
This review protocol followed the Cochrane Handbook;
PRISMA-P, PRISMA, and MOOSE guidelines; and Guid-
ance on the Conduct of Narrative Synthesis in Systematic
Reviews [18–22], which guide the preparation and reporting
of protocols, systematic reviews, and meta-analyses. They
collectively led to the development of systematically defined
inclusion and exclusion criteria, an analytical framework and
a structure for writing up the protocol. Any changes from
these protocols, along with the justification for these changes,
are listed below. Table 4 in Appendix displays the completed
PRISMA-P checklist.Inclusion criteria
Publications will be eligible for inclusion in this review if
they meet the following requirements:
Participants: Women > 15 years of age with no major co-
morbidities and no CVD before pregnancy.
Exposures and comparators: Any of the following:
1. Miscarriage: pregnancy loss that is spontaneous,
involuntary, and occurs before 28 weeks of gestation
prior to the 1st of October 1992, and before 24 weeks
after this date [23]. Studies which do not report a
definition will still be included.
Comparator: women who have not experienced or
reported any miscarriages.2. Stillbirth: pregnancy loss that occurs at 28 or more
weeks of gestation prior to the 1st of October 1992,
and after 24 weeks after this date [24].
Comparator: women who have not experienced or
reported any stillbirths.
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whether viable or non-viable, so that it does not result in
the birth of a child [25]. No distinction will be made
between medical abortion and surgical abortion in this
systematic review, nor will distinctions be made on the
grounds for abortion (e.g., problems identified in the em-
bryo vs abortion related to the pregnant women’s health)
Comparator: women who have not experienced or
reported any abortions.Outcomes: any of the following: (1) total CVD, (2) CHD,
(3) total stroke, (4) ischemic stroke, (5) hemorrhagic stroke,
(6) myocardial infarction, and (7) transient ischemic attack.
Study design: Cohort of case-control studies, which in-
clude a measure which includes a measure of association
or the raw data to calculate one.
Exclusion criteria
Publications which solely used neonatal deaths or ectopic
pregnancies as exposures will be excluded in order to
minimize heterogeneity in exposure measures. Editorials,
protocols, and conference proceedings will not be in-
cluded in the review due to the lack of methodological de-
tails. Publications evaluating only CVD risk factors, and
those combining different exposure groups together (e.g.,
miscarriage and stillbirth as a single exposure group) will
not be eligible. Papers will not be excluded based on the
grounds for abortion (e.g., health of the embryo vs health
of the pregnant woman), nor the medical treatment re-
ceived for pregnancy loss (e.g., medical vs surgical), nor
the gestational duration of the pregnancy when it ended.
To ensure a high level of interrater consistency, a
consistency check will be carried out prior to the screen-
ing of results using the kappa statistic. This check will
be conducted through the application of the selection
criteria by 4 reviewers independently to a 20% random
sample of the results of the systematic searches at the
title/abstract stage. Following this, the criteria will be
further refined, if required, in order to support consist-
ent interpretation between members of the review team.
Information sources
The following databases will be systematically searched
for relevant publications: MEDLINE (through PubMed),
Scopus, Web of Knowledge, the CINAHL Nursing Data-
base, and the Cochrane Library. To optimize this sys-
tematic literature search, the reference lists of identified
studies and related reviews will also be manually
screened for other pertinent publications meeting our
inclusion criteria.
Search strategy
To ensure the search strategy is as comprehensive as pos-
sible, a search of MEDLINE will be performed using aninitial set of search terms created from MeSH & thesaurus
terms (Table 1). The titles and abstracts from this search will
be assessed for any additional relevant search terms. If any
are identified, they will be included in the final, comprehen-
sive search strategy.
No restrictions on the publication period, geography,
or language of the articles will be included as part of the
search methodology. This is in order to ensure that the
results are as complete as possible. Searches will not be
limited to titles or abstracts; medical search headings
and open-text fields will be used in the database
searches to return publications. The search in MEDLINE
will be limited to humans.
Final search terms for the exposure (e.g., pregnancy
loss) and outcome (e.g., CVD) are shown in Table 2.
While this review in part updates a previously published
systematic review and meta-analysis [17] which included
results published prior to December 2011, additional
search terms have also been included. Therefore, there
will be no restrictions on the publication period of the
search to ensure all relevant results are identified.
Study selection
A database compiled using CADIMA, a tool supporting the
conduct and reporting of systematic reviews [26] will be used
for screening eligible publications. Following deduplication,
studies will be screened for inclusion using a hierarchical re-
view methodology: all titles and abstracts will be reviewed,
and the full texts and supporting data of potentially relevant
publications identified at this stage will then assessed.
Each study will be independently screened for eligibility
by two members of the review team, against predefined in-
clusion criteria. Any disagreements will be resolved through
discussion between the two reviewers; however, if consen-
sus cannot be reached, a third reviewer will be consulted.
All publications selected for inclusion in this study will be
approved by a senior investigator. The numbers of publica-
tions reviewed, full-text studies retrieved, and studies ex-
cluded will be reported using the PRISMA flow chart.
If multiple publications are found to use the same pri-
mary data from the same individuals, the publication
with a greater number of participants, preferably, or al-
ternatively greater analytical detail will be included in
this study and related meta-analysis.
Data extraction
Data collection from relevant studies will be standard-
ized using a data extraction template. The template has
been informed by the recommendations made in the
Cochrane Handbook of Systematic Reviews of Interven-
tions [20], which was adapted to reflect this review’s
focus on non-intervention studies. Data collected will in-
clude the lead author, study country, year of publication,
study design, population studied, exposure (including
Table 1 Search terms and number of articles found from a preliminary PubMed search
Step Search term Articles found
(n)a
#1 “Spontaneous Abortion” OR “Habitual Abortion” OR “Recurrent Abortion” OR “Recurrent Miscarriage” OR “Habitual Miscarriage”
OR “Miscarriage” OR “Foetal Death” OR “Fetal Death” OR “Pregnancy Loss” OR “therapeutic abortion” OR “stillbirtha” OR “still
birth” OR “still-birth” OR “still borna” OR “abortiona” OR “induced abortiona”
49,041
#2 “Cardiovascular Disease” OR “Coronary Artery Disease” OR “Myocardial Infarction” OR “Heart Attack” OR “Coronary Heart
Disease” OR “Ischemic Heart Disease” OR “Ischaemic Heart Disease” OR “Stroke” OR “Transient Ischemic Attack” OR “Transient
Ischaemic Attack” OR “Vascular Accident” OR “Apoplexy” OR “cerebrovascular diseasea” OR “TIA” OR “CVA” OR “cva” OR “CVD”
OR “cardio-vascular disease” OR “Coronary Artery Bypass Graft”
769,180
#3 #1 AND #2 (filtered to humans) 421
aPreliminary search conducted on May 7, 2019
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number of cases, number of non-cases, the association
measure, point estimate and 95% confidence intervals
(CI), and any adjustment/stratification/matching vari-
ables [17]. Furthermore, there will be an open-text field
to include any additional comments. In cases of missing
or incomplete information in the included studies, we
will contact study authors for further information, re-
contacting after 2 weeks if no response is received.
Where English language versions of publications are re-
quired, members of the review team will have the article
translated.Data synthesis and statistical analysis
Exposure analysis subgroups
In order to ensure comparability and minimize heterogen-
eity in exposure measures, the different exposure sub-
groups will be considered in several ways in the meta-
analyses of results. They are summarized in Table 3.
All exposures will be compared with control groups with-
out a history of the particular exposure in question. Where
studies are deemed eligible for inclusion, but do not provide
the required association measure, the raw data available in
the study will be used to calculate an unadjusted estimate.Outcome analysis subgroups
Both fatal and non-fatal occurrences of the following
outcomes are eligible: CVD, CHD, MI, ischemic stroke,
hemorrhagic stroke, and transient ischemic attacks.
Given the hierarchical nature of some of these out-
comes, meta-analyses will evaluate grouped outcomes:Table 2 Search terms used in the full systematic literature search
Exposure “Spontaneous Abortion” “Habitual Abortion” “Recurrent Abortion”
Death” “Fetal Death” “Pregnancy Loss” “therapeutic abortion” “stil
abortion*”
Outcome “Cardiovascular Disease” “Coronary Artery Disease” “Myocardial In
“Ischaemic Heart Disease” “Stroke” “Transient Ischemic Attack” “Tr
disease*” “TIA” “CVA” “cva” “CVD” “cardio-vascular disease” “Coron
Non-underlined text: search terms from 2013 review and meta-analysis
Underlined text: additional search terms included in this review1) CVD: all cardiovascular disease unless reported as a
subtype only.
2) CHD: incorporating any individuals with diagnoses
of CHD, MI, and individuals with a history of
Coronary Artery Bypass Graft.
3) Cerebrovascular disease: incorporating ischemic
stroke and hemorrhagic stroke.
A narrative synthesis of results will be presented, with the
findings of individual studies reported both in tables and text.
Meta-analyses will be conducted if three or more studies are
found assessing a particular exposure-outcome combination.
Given previous meta-analyses, we anticipate variability be-
tween included studies; therefore, a random-effects inverse
variance-weighted model will be used to combine reported
measures of association to produce a pooled odds ratio with
95% CI. The results will be displayed in forest plots separ-
ately for adjusted and unadjusted meta-analyses.
Between-study heterogeneity will be assessed using the I2
statistic and the Cochrane χ2 statistic [20]. I2 values of ≤ 50%,
50–75%, and 75–100% will be considered low, moderate,
and high, respectively. If moderate or high levels of between-
study heterogeneity are identified in meta-analyses of more
than six studies, then meta-regression will be conducted to
assess the relationship between the magnitude of risk and
study characteristics of interest, including the age of partici-
pants, duration of follow-up, and year of study [27].
Small study effects will be evaluated by funnel plots and
Egger’s test for meta-analyses that include six or more stud-
ies [20]. The Cochrane Handbook recommends at least ten
studies to be included in a funnel plot; therefore, we acknow-
ledge that there may be insufficient power to detect real
asymmetry from chance [20]. Based on previous reviews, it is“Recurrent Miscarriage” “Habitual Miscarriage” “Miscarriage” “Foetal
l birth*” “still-birth*” “stillbirth*” “still born*” “abortion*” “induced
farction” “Heart Attack” “Coronary Heart Disease” “Ischemic Heart Disease”
ansient Ischaemic Attack” “Vascular Accident” “Apoplexy” “cerebrovascular
ary Artery Bypass Graft”
Table 3 The proposed different categorizations of the three forms of pregnancy loss
Miscarriage A history of miscarriage:
one or more miscarriages
Recurrent miscarriage: multiple miscarriages, defined in
publications as a history of 2+ or 3+ miscarriages
Dose-response relationship: the number of
miscarriages categorized as 0, 1, 2, and 3 or
more
Stillbirth A history of stillbirth: one
or more stillbirths
Recurrent stillbirth: multiple stillbirths, defined in
publications as a history of 2+ or 3+ stillbirths
Dose-response relationship: the number of
stillbirths categorized as 0, 1, 2, and 3 or more
Abortion A history of abortion: one
or more abortions
Recurrent abortion: multiple abortions, defined in
publications as a history of 2+ or 3+ abortions
Dose-response relationship: the number of
abortions categorized as 0, 1, 2, and 3 or more
In all cases, the analyses will be conducted if sufficient studies are identified
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therefore, we have chosen a more lenient cut-off, whilst be-
ing mindful not to over-interpret the results.
If there is evidence of funnel plot asymmetry and indica-
tion of significant bias from the Egger’s test, the trim-and-
fill method will be used to correct for the asymmetry [28].
A number of sensitivity analyses will be considered.
The first analysis will exclude studies with the largest ef-
fect estimates to assess the impact of these studies on
the magnitude of the pooled result and the observed het-
erogeneity. The second analysis will include all studies
and will re-run each meta-analysis with fixed-effects
models to assess the consistency of the results.
Stratified analyses will also be considered where there
are at least two studies in each strata. These analyses will
stratify by (1) different levels of adjustment, (2) the
population studied (e.g., N. American vs European), and
(3) the level of bias in individual studies (as assessed by
Newcastle-Ottawa Scale [NOS]).
P values of less than 0.05 will be considered to be sig-
nificant. Analyses will be completed in Stata version 15
(StataCorp, College Station, TX, USA).Data quality and strength of evidence
Methodological quality and risk of bias within each of
the included studies will be evaluated using the vali-
dated NOS for assessing the internal validity of case-
control or cohort studies [29]. The NOS was chosen
as it can assess the quality of both case-control and
cohort studies, providing a comparable measure of
quality for both study designs. The NOS uses a semi-
quantitative scale for assessing the quality of non-
randomized studies and allocates a maximum of nine
stars to a study, across three categories. The categor-
ies are the quality of studies on the participant selec-
tion criteria, comparability of cases and controls, and
exposure assessment (for case-control studies) or out-
come assessment (for cohort studies).
The strength of the evidence for each exposure-
outcome association will be assessed using the GRADE
approach. This approach will assess the study limitations,
providing an overall rating of the confidence in the results
of each exposure-outcome association [30].Discussion
To our knowledge, this systematic review will be the first in
the field to consider the full breadth of literature regarding
the association between pregnancy loss and future maternal
CVD. This protocol will add to the collective literature on
systematic review protocols, of which there are few specific-
ally addressing women’s health and CVD. This topic has its
own unique challenges, including formulating precise inclu-
sion and exclusion criteria that define pregnancy loss sub-
types accurately. In particular, the gestational age
boundaries for stillbirth, abortion, and miscarriage have
changed over time [31]. Careful consideration is also re-
quired for the synthesis of data in which the exposure was
reported in different categories (for example: 0 vs 1+; and 0,
1, 2, vs 3+). In order to accommodate potential differences,
a narrative as well as a quantitative approach has been pro-
posed to ensure all findings are reported.
Our proposed review has a number of strengths. It
builds upon several sets of guidelines (MOOSE, PRISMA,
Cochrane Handbook, and the Guidance on the Conduct
of Narrative Synthesis in Systematic Reviews). Its novel
scope has importance for academics, clinicians, and indi-
vidual patients. The results of this review have the poten-
tial to inform the development of future risk assessment
tools, such as the QRISK3 scoring tool [32], and aid doc-
tors and patients in making informed clinical choices.
However, limitations are also anticipated. Although,
stringent inclusion and exclusion will be applied, with a
view to reducing between-study heterogeneity, hetero-
geneity is expected and will be assessed. Potential
sources of heterogeneity include (1) differences in
obtaining exposure information, such as self-reported vs
medically verified pregnancy loss; (2) inconsistent or in-
sufficient adjustment for confounding factors, including
medical, psychosocial, and lifestyle factors such as de-
pression, smoking, obesity, and hypertension; (3) popula-
tion differences in the availability of abortions and the
social acceptability of reporting them; and (4) differences
in follow-up duration, if the magnitude of risk varies by
time since the pregnancy loss.
Any protocol changes to address unforeseen limitations
will be made through group discussion, and the date and
rationale for the changes will be recorded in PROSPERO.
Results of this systematic review, and associated meta-
Appendix
Table 4 PRISMA-P Checklist
Section and topic Item
No
Checklist item Page
number
Administrative information
Title
Identification 1a Identify the report as a protocol of a systematic review 1
Update 1b If the protocol is for an update of a previous systematic review, identify as such 2
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number 1
Authors
Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing ad-
dress of corresponding author
1
Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review 7
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as
such and list changes; otherwise, state plan for documenting important protocol amendments
n/a
Support
Sources 5a Indicate sources of financial or other support for the review 7
Sponsor 5b Provide name for the review funder and/or sponsor n/a
Role of sponsor or
funder
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol 7
Introduction
Rationale 6 Describe the rationale for the review in the context of what is already known 2
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants,
interventions, comparators, and outcomes (PICO)
2-3
Methods
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report
characteristics (such as years considered, language, publication status) to be used as criteria for eligibility
for the review
3-4
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial
registers or other grey literature sources) with planned dates of coverage
3-4, 5
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits,
such that it could be repeated
Table 3
Study records
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 3-4
Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through
each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
3-4
Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently,
in duplicate), any processes for obtaining and confirming data from investigators
3-4
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any
pre-planned data assumptions and simplifications
3-4
Outcomes and
prioritization
13 List and define all outcomes for which data will be sought, including prioritization of main and
additional outcomes, with rationale
3-4
Risk of bias in individual
studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will
be done at the outcome or study level, or both; state how this information will be used in data
synthesis
5
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 4
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of
handling data and methods of combining data from studies, including any planned exploration of
consistency (such as I2, Kendall’s τ)
4-5
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 4-5
15d If quantitative synthesis is not appropriate, describe the type of summary planned 4
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Table 4 PRISMA-P Checklist (Continued)
Section and topic Item
No
Checklist item Page
number
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective
reporting within studies)
4-5
Confidence in
cumulative evidence
17 Describe how the strength of the body of evidence will be assessed (such as GRADE) GRADE
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relevant, peer-reviewed journal, presented at conferences,
and disseminated to the public through media outlets.
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